Lv11
68 积分 2022-03-09 加入
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
1小时前
待确认
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
1小时前
已完结
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
10天前
已完结
皖公网安备34019202002308
